Vimarsana
Biggest News Aggregation in the World

Page 7 - Cameron Durrant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cameron Durrant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cameron Durrant Today - Breaking & Trending Today

Cybersecurity: The 5 Things Leaders Need to Know - Vimarsana News

Cybersecurity: The 5 Things Leaders Need to Know

New York, NY (PRWEB) January 15, 2022 -- Every business relies on technology. That means every company is now vulnerable to cyberattacks. Most who get

Source: prweb.com
Humanigen, Inc.: Humanigen to Present at Investor Conferences January 7 and 13, 2022 - Vimarsana News

Humanigen, Inc.: Humanigen to Present at Investor Conferences January 7 and 13, 2022

Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm,' announced that Cameron Durrant

Humanigen to Present at Investor Conferences January 7 and 13, 2022 - Vimarsana News

Humanigen to Present at Investor Conferences January 7 and 13, 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels - Vimarsana News

Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels

03.01.2022 - Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that a manuscript ... Seite 1

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results - Vimarsana News

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

02.12.2021 - Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced today The Lancet ... Seite 1